The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

Provided subject matter relates to tissue engineering. More specifically provided are kits, devices and methods for in situ repair and regeneration of guided and functional growth of cells and cell components by providing into the injury site biomaterial solution including the cell(s), magnetic particles and solidifying the biomaterial while applying the magnetic field.

Provided subject matter relates to tissue engineering. More specifically provided are kits, devices and methods for in situ repair and regeneration of guided and functional growth of cells and cell components by providing into the injury site biomaterial solution including the cell(s), magnetic particles and solidifying the biomaterial while applying the magnetic field.

Composite nerve guides for nerve regeneration are provided, wherein the composite guide comprise a nerve graft and a nerve conduit continuing an active agent that promote axon regeneration. The devices can provide structural supports to guide nerve regeneration and locally deliver an active agent (e.g., glial cell-line derived neurotrophic factor (GDNF) and/or glial growth factor 2 (GGF2) to injured nervous system tissue upon implantation in a subject. Methods of treatment using such devices are also provided.

The present invention relates to a pharmaceutical composition comprising glia-like cells differentiated from human mesenchymal stem cells as an active ingredient for treatment of stroke. Specifically, as a result of injecting the glia-like cells differentiated from human mesenchymal stem cells (ghMSCs) of the present invention to cerebral infarction-induced animal models, the infarct volume remarkably decreased by 50% or more and neural functions were remarkably improved, compared to a control group and a group treated with human mesenchymal stem cells (hMSCs), demonstrating that ischemic stroke (infarction) is treated by the Akt pathway of IGFBP-4 via IGF-1R. Thus, the differentiated glia-like cells of the present invention can be advantageously used as a cell therapy product for stroke.

The present invention relates to a pharmaceutical composition comprising glia-like cells differentiated from human mesenchymal stem cells as an active ingredient for treatment of stroke. Specifically, as a result of injecting the glia-like cells differentiated from human mesenchymal stem cells (ghMSCs) of the present invention to cerebral infarction-induced animal models, the infarct volume remarkably decreased by 50% or more and neural functions were remarkably improved, compared to a control group and a group treated with human mesenchymal stem cells (hMSCs), demonstrating that ischemic stroke (infarction) is treated by the Akt pathway of IGFBP-4 via IGF-1R. Thus, the differentiated glia-like cells of the present invention can be advantageously used as a cell therapy product for stroke.

The present invention relates to a method for preparing an induced pluripotent stem cell line from mesenchymal stem cells; and an induced pluripotent stem cell line (deposit number: KCLRF-BP-00318) obtained thereby. Specifically, the method for preparing an induced pluripotent stem cell line, of the present invention, comprises the steps of: (a) obtaining mesenchymal stem cells from a human umbilical cord; (b) forming, from the mesenchymal stem cells, a colony with a medium for dedifferentiation containing an Ecklonia cava extract; and (c) obtaining an induced pluripotent stem cell line by sub-culturing the colony. The induced pluripotent stem cell line according to the present invention was first established by the present inventors, and the pluripotent stem cell line of the present invention can be differentiated into various cells and can treat various diseases or disorders through cell transplant therapy.

The present invention relates to a method for preparing an induced pluripotent stem cell line from mesenchymal stem cells; and an induced pluripotent stem cell line (deposit number: KCLRF-BP-00318) obtained thereby. Specifically, the method for preparing an induced pluripotent stem cell line, of the present invention, comprises the steps of: (a) obtaining mesenchymal stem cells from a human umbilical cord; (b) forming, from the mesenchymal stem cells, a colony with a medium for dedifferentiation containing an Ecklonia cava extract; and (c) obtaining an induced pluripotent stem cell line by sub-culturing the colony. The induced pluripotent stem cell line according to the present invention was first established by the present inventors, and the pluripotent stem cell line of the present invention can be differentiated into various cells and can treat various diseases or disorders through cell transplant therapy.

The present invention provides an improved method of producing highly pure retinal pigment epithelial (RPE) cells by differentiation of pluripotent stem cells.